Cargando…
Bosutinib‐associated interstitial lung disease and pleural effusion: A case report and literature review
Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145267/ https://www.ncbi.nlm.nih.gov/pubmed/34094551 http://dx.doi.org/10.1002/ccr3.3164 |